

Masayuki Amano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7428217/publications.pdf>

Version: 2024-02-01

53
papers

1,380
citations

331538

21
h-index

360920

35
g-index

59
all docs

59
docs citations

59
times ranked

1175
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization. <i>Journal of Biological Chemistry</i> , 2007, 282, 28709-28720.	1.6	137
2	Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4-ethynyl-2-fluoro-2-deoxyadenosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2701-2708.	1.4	96
3	In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors. <i>Journal of Virology</i> , 2010, 84, 11961-11969.	1.5	85
4	Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P ₂ Ligands: Structure-Activity Studies and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 622-634.	2.9	69
5	A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2143-2155.	1.4	66
6	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
7	Probing Multidrug-Resistance and Protein-Ligand Interactions with Oxatricyclic Designed Ligands in HIV-1 Protease Inhibitors. <i>ChemMedChem</i> , 2010, 5, 1850-1854.	1.6	47
8	4'-modified nucleoside analogs: Potent inhibitors active against entecavir-resistant hepatitis B virus. <i>Hepatology</i> , 2015, 62, 1024-1036.	3.6	43
9	Highly Potent HIV-1 Protease Inhibitors with Novel Tricyclic P ₂ Ligands: Design, Synthesis, and Protein-Ligand X-ray Studies. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6792-6802.	2.9	42
10	Design, Synthesis, Protein-Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug Resistance. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7689-7705.	2.9	40
11	Loss of Protease Dimerization Inhibition Activity of Darunavir Is Associated with the Acquisition of Resistance to Darunavir by HIV-1. <i>Journal of Virology</i> , 2011, 85, 10079-10089.	1.5	40
12	GRL-02031, a Novel Nonpeptidic Protease Inhibitor (PI) Containing a Stereochemically Defined Fused Cyclopentanyltetrahydrofuran Potent against Multi-PI-Resistant Human Immunodeficiency Virus Type 1 In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 997-1006.	1.4	38
13	Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. <i>Free Radical Biology and Medicine</i> , 2013, 65, 778-788.	1.3	32
14	Design of HIV-1 Protease Inhibitors with C3-Substituted Hexahydrocyclopentafuranyl Urethanes as P ₂ -Ligands: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Crystal Structure. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5890-5901.	2.9	31
15	Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P ₂ Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4561-4577.	2.9	31
16	Design, Synthesis, and X-ray Structure of Substituted Bis-tetrahydrofuran (Bis-THF)-Derived Potent HIV-1 Protease Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 298-302.	1.3	26
17	Loss of the Protease Dimerization Inhibition Activity of Tipranavir (TPV) and Its Association with the Acquisition of Resistance to TPV by HIV-1. <i>Journal of Virology</i> , 2012, 86, 13384-13396.	1.5	26
18	Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P ₂ -ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4903-4909.	1.0	26

#	ARTICLE	IF	CITATIONS
19	Novel HIV-1 Protease Inhibitors (PIs) Containing a Bicyclic P2 Functional Moiety, Tetrahydropyrano-Tetrahydrofuran, That Are Potent against Multi-PI-Resistant HIV-1 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1717-1727.	1.4	25
20	GRL-0519, a Novel Oxatricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2036-2046.	1.4	24
21	Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. <i>Cancer Science</i> , 2019, 110, 3275-3287.	1.7	23
22	Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	23
23	Novel Protease Inhibitors (PIs) Containing Macrocyclic Components and 3(R),3a(S),6a(T) Tj ETQq1 1 0.784314 rgBT /C Variants <i>In Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3460-3470.	1.4	21
24	GRL-04810 and GRL-05010, Difluoro-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 <i>In Vitro</i> and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6110-6121.	1.4	21
25	Structure-Based Design of Potent HIV-1 Protease Inhibitors with Modified P1-Biphenyl Ligands: Synthesis, Biological Evaluation, and Enzyme-Inhibitor X-ray Structural Studies. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5334-5343.	2.9	21
26	Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 6842-6854.	1.5	20
27	Design of Difluoro-bis-Tetrahydrofuran as P2 Ligand for HIV-1 Protease Inhibitors to Improve Brain Penetration: Synthesis, X-ray Studies, and Biological Evaluation. <i>ChemMedChem</i> , 2015, 10, 107-115.	1.6	20
28	Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4867-4879.	2.9	19
29	Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2308-2311.	1.0	17
30	Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5114-5127.	1.4	16
31	GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants <i>in vitro</i> . <i>Scientific Reports</i> , 2017, 7, 12235.	1.6	16
32	Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1241-1246.	1.0	14
33	A Modified P1 Moiety Enhances <i>In Vitro</i> Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and <i>In Vitro</i> Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7046-7059.	1.4	14
34	Diastereoselective Synthesis of 6-(Z)- and 6-(E)-Fluoro Analogues of Anti-hepatitis B Virus Agent Entecavir and Its Evaluation of the Activity and Toxicity Profile of the Diastereomers. <i>Journal of Organic Chemistry</i> , 2016, 81, 2827-2836.	1.7	12
35	Novel Protease Inhibitors Containing C-5-Modified-bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2 Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	11
36	A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0103921.	1.4	11

#	ARTICLE	IF	CITATIONS
37	A Novel Tricyclic Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor, GRL-0739, Effectively Inhibits the Replication of Multidrug-Resistant HIV-1 Variants and Has a Desirable Central Nervous System Penetration Property <i>in Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2625-2635.	1.4	10
38	Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 11607-11621.	1.5	10
39	Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PLI.1 up-regulation in myeloma cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 236-242.	1.0	10
40	Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	9
41	Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2 Ligands of Darunavir. <i>ChemMedChem</i> , 2017, 12, 1942-1952.	1.6	8
42	Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1-P2 ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4925-4931.	1.0	7
43	Synthesis, Anti-HBV, and Anti-HIV Activities of 3-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 1211-1216.	1.3	7
44	A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
45	Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2 Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan. <i>Journal of Infectious Diseases</i> , 2022, 226, 2038-2039.	1.9	7
46	A novel entecavir analogue constructing with a spiro[2.4]heptane core structure in the aglycon moiety: Its synthesis and evaluation for anti-hepatitis B virus activity. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2017, 36, 463-473.	0.4	6
47	Synthesis of 4-Substituted Purine 2-Deoxynucleosides and Their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. <i>ChemistrySelect</i> , 2018, 3, 3313-3317.	0.7	6
48	Amino-acid inserts of HIV-1 capsid (CA) induce CA degradation and abrogate viral infectivity: Insights for the dynamics and mechanisms of HIV-1 CA decomposition. <i>Scientific Reports</i> , 2019, 9, 9806.	1.6	5
49	Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors <i>in Vitro</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0171521.	1.4	5
50	Design, Synthesis, and Evaluation of Anti-HBV Activity of Hybrid Molecules of Entecavir and Adefovir: Exomethylene Acycloguanine Nucleosides and Their Monophosphate Derivatives. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2015, 34, 590-602.	0.4	4
51	Synthesis and evaluation of the anti-hepatitis B virus activity of 4-Azido-thymidine analogs and 4-Azido-2-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2020, 39, 518-529.	0.4	2
52	Design, Synthesis and X-ray Structural Studies of Potent HIV-1 Protease Inhibitors Containing 4-Substituted Tricyclic Hexahydrofurofuran Derivatives as P2 Ligands. <i>ChemMedChem</i> , 2022, 17, .	1.6	2
53	Correlates of Neutralizing/SARS-CoV-2-S1-Binding Antibody Response With Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0